other_material
confidence high
sentiment positive
materiality 0.65
Tonix TNX-801 vaccine data: 100,000-fold less virulent, s.c. route protective
Tonix Pharmaceuticals Holding Corp.
- TNX-801 is up to 100,000-fold less virulent than licensed vaccinia in interferon receptor knockout mice.
- Subcutaneous administration yields equivalent protection to percutaneous route; company plans s.c. product first.
- Single dose protected all vaccinated macaques from lethal Clade I mpox challenge without lesions.
- Rabbit models remained fully protected for 14 months post single dose.
- Company to advance TNX-801 into clinic via subcutaneous delivery for mpox and smallpox prevention.
item 7.01item 8.01item 9.01